Use this identifier to quote or link this document: http://hdl.handle.net/2072/229117

Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics
Martínez-Clemente, José; López-Arnau, Raúl; Carbó Banús, Marcel·lí; Pubill Sánchez, David; Camarasa García, Jordi; Escubedo Rafa, Elena
Rationale Mephedrone (4-methylmethcathinone) is a still poorly known drug of abuse, alternative to ecstasy or cocaine. Objective The major aims were to investigate the pharmacokineticsa and locomotor activity of mephedrone in rats and provide a pharmacokinetic/pharmacodynamic model. Methods Mephedrone was administered to male Sprague
Dawley rats intravenously (10 mg/kg) and orally (30 and 60 mg/kg). Plasma concentrations and metabolites were characterized using LC/MS and LC-MS/MS fragmentation patterns. Locomotor activity was monitored for 180
240 min. Results Mephedrone plasma concentrations after i.v. administration fit a two-compartment model (α=10.23 h−1, β=1.86 h−1). After oral administration, peak mephedrone concentrations were achieved between 0.5 and 1 h and declined to undetectable levels at 9 h. The absolute bioavailability of mephedrone was about 10 % and the percentage of mephedrone protein binding was 21.59±3.67%. We have identified five phase I metabolites in rat blood after oral administration. The relationship between brain levels and free plasma concentration was 1.85±0.08. Mephedrone induced a dose-dependent increase in locomotor activity, which lasted up to 2 h. The pharmacokinetic
pharmacodynamic model successfully describes the relationship between mephedrone plasma concentrations and its psychostimulant effect. Conclusions We suggest a very important first-pass effect for mephedrone after oral administration and an easy access to the central nervous system. The model described might be useful in the estimation and prediction of the onset, magnitude,and time course of mephedrone pharmacodynamics as well as to design new animal models of mephedrone addiction and toxicity.
2014-05-14
Amfetamines
Sistema nerviós central
Cervell
Farmacocinètica
Efectes fisiològics
Drogues de disseny
Amphetamines
Central nervous system
Brain
Pharmacokinetics
Physiological effect
Designer drugs
(c) Springer Verlag, 2013
Article
info:eu-repo/semantics/acceptedVersion
Springer Verlag
         

Show full item record

Related documents

Other documents of the same author

López-Arnau, Raúl; Martínez-Clemente, José; Carbó Banús, Marcel·lí; Pubill Sánchez, David; Escubedo Rafa, Elena; Camarasa García, Jordi
López-Arnau, Raúl; Martínez-Clemente, José; Carbó Banús, Marcel·lí; Pubill Sánchez, David; Escubedo Rafa, Elena; Camarasa García, Jordi
Martínez-Clemente, José; López-Arnau, Raúl; Carbó Banús, Marcel·lí; Pubill Sánchez, David; Camarasa García, Jordi; Escubedo Rafa, Elena
López-Arnau, Raúl; Martínez-Clemente, José; Abad, Sonia; Pubill Sánchez, David; Camarasa García, Jordi; Escubedo Rafa, Elena
Martínez-Clemente, José; López-Arnau, Raúl; Abad, Sonia; Pubill Sánchez, David; Escubedo Rafa, Elena; Camarasa García, Jordi
 

Coordination

 

Supporters